FUTURE-SUPER

NCT04395989 📎

Regimen

Experimental
Subtype-matched therapy (e.g., pyrotinib for LAR, camrelizumab+nab-paclitaxel for IM, nab-paclitaxel+bevacizumab for BLIS, etc.) on top of nab-paclitaxel backbone.
Control
Nab-paclitaxel 125 mg/m2 d1, d8, d15 q4w monotherapy.

Population

Previously untreated metastatic triple-negative breast cancer, stratified by FUDAN-TNBC molecular subtype (luminal AR, immunomodulatory, basal-like IR, mesenchymal).

Key finding

FUTURE-SUPER established Fudan proprietary TNBC molecular subtyping (FUSCC/Shao) as prospectively actionable, with subtype-matched therapy more than doubling PFS vs nab-paclitaxel alone in 1L mTNBC. Proof-of-concept for precision TNBC.

Source: PMID 38211606

Timeline

  • Publication: 2024 Feb

Guideline citations

  • NCCN BREAST